302
Participants
Start Date
March 17, 2020
Primary Completion Date
April 20, 2022
Study Completion Date
April 20, 2022
Fezolinetant
Oral
Placebo
Oral
Site CN86001, Beijing
Site CN86002, Beijing
Site CN86017, Beijing
Site CN86030, Beijing
Site CN86022, Changchun
Site CN86009, Changsha
Site CN86037, Chengdu
Site CN86006, Guangzhou
Site CN86019, Guangzhou
Site CN86042, Guangzhou
Site CN86043, Guangzhou
Site CN86018, Guiyang
Site CN86025, Hangzhou
Site CN86034, Hangzhou
Site CN86027, Kunming
Site CN86005, Liuzhou
Site CN86004, Nanjing
Site CN86011, Nanjing
Site CN86035, Nanjing
Site CN86026, Nanning
Site CN86012, Shanghai
Site CN86021, Shenzhen
Site CN86007, Shijiazhuang
Site CN86023, Taiyuan
Site CN86031, Taiyuan
Site CN86015, Tianjin
Site CN86029, Tianjin
Site CN86008, Wuhan
Site CN86041, Yangzhou
Site CN86013, Yinchuan
Site CN86033, Zhongshan
Site KR82013, Ansan-si
Site KR82005, Busan
Site KR82003, Seongnam-si
Site KR82011, Seongnam-si
Site KR82001, Seoul
Site KR82002, Seoul
Site KR82004, Seoul
Site KR82006, Seoul
Site KR82012, Seoul
Site TW88608, Kaohsiung City
Site TW88604, New Taipei City
Site TW88606, Taichung
Site TW88603, Tainan City
Site TW88609, Tainan City
Site TW88601, Taipei
Site TW88607, Taipei
Site TW88611, Taipei
Astellas Pharma China, Inc.
INDUSTRY